[A25-58] Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-58
Commission:
Commission awarded on 30.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Monotherapy for the treatment of adult and paediatric patients twelve years of age and older with advanced solid tumours expressing a NTRK gene fusion
- Patients who have not previously received an NTRK inhibitor and for whom treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted: added benefit not proven
- Patients who have previously received an NTRK inhibitor: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-58
| Project no. | Title | Status |
|---|---|---|
| A25-59 | Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |